Article
Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.
Journal of viral hepatitis - 1 Feb 2015
Cortesi P A, Ciaccio A, Rota M, Lim J K, De Salvia S, Okolicsanyi S, Vinci M, Belli L S, Mantovani L G, Strazzabosco M
Abstract excerpt
New and more promising therapies for chronic hepatitis C (CHC) genotype 1 (G1) naive patients have recently been approved in the United States and Europe, and several more regimens are expected to become available within the next several years. While this scenario unfolds, it is necessary to develop a rational method to allocate current treatment in CHC G1 patients. We performed a cost-effectiveness analysis of...
Topics
- Adult
- Aged
- Antiviral Agents
- Cost-Benefit Analysis
- Drug Therapy, Combination
- Genotype
- Hepacivirus
- Hepatitis C, Chronic
- Humans
- Italy
- Middle Aged
- Oligopeptides
- Proline
- Prospective Studies